An Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Advanced or Metastatic Solid Cancer for Whom Curative Therapy is Unavailable

NCT00582985 Phase 1 COMPLETED

This study is being performed to evaluate the safety and tolerability of the TRC105 monoclonal antibody.

Details

Lead sponsor	Tracon Pharmaceuticals Inc.
Phase	Phase 1
Status	COMPLETED
Enrolment	51
Start date	2007-12
Completion	2011-06

Conditions

• Cancer
• Neoplasm Metastasis

Interventions

• TRC105 chimeric anti-CD105 antibody

Primary outcomes

• Safety and Tolerability will be evaluated — Through last patient last visit
• Dose Limiting Toxicities — 28 day evaluation period

Countries

United States